Key clinical point: Researchers have found they can screen pediatric cancer patients for genetic alterations and match those patients to appropriate targeted therapies.

Major finding: Thus far, 24% of the patients screened have been matched and assigned to a treatment, and 10% have been enrolled on treatment protocols.

Study details: Ongoing Pediatric MATCH trial, which has enrolled 422 patients so far.

Disclosures: The trial is sponsored by the National Cancer Institute. The presenter has patents, royalties, and other intellectual property related to genes discovered through sequencing of several adult cancer types.